Iadademstat + SBRT With Atezo in ES-SCLC

This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.

NCT Number	NCT07113691
Lead Sponsor	Yale University Collaborators: Genentech, Inc., Oryzon Genomics S.A.
Conditions	Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment	15 participants
Start Date	2026-01-20
Primary Completion	2030-01 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-27